Kymera Therapeutics (KYMR) AI Stock Analysis

• Market Cap: $2.87B
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.47
• Revenue Growth: -25.85%
• EPS Growth: -23.89%
• Country: US
• Employees: 208
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 65,119,570
• 10 Day Avg. Volume: 1,000,208
• 30 Day Avg. Volume: 1,087,679
• PEG Ratio: -0.38
• Price to Book (P/B): -19.91
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 85.25
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 5.06
• Enterprise Value/Gross Profit: 24.22
• Enterprise Value/Ebitda: -1.87
• 1Y Price Target: $62.27
• Price Target Upside: 41.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 17

• Rating: 60 Neutral
• Price Target: $50.00 ▲(13.33%Upside)

Kymera Therapeutics benefits from strong technical momentum and strategic corporate partnerships, which enhance its growth outlook despite current financial challenges. The company's substantial cash reserves and promising pipeline developments further support future potential, although the negative cash flow and earnings remain significant risks.

Positive Factors

Financial Outlook

The pipeline now contributes $26/share (previously $20).

Product Development

The decision to advance next-gen IRAK4 degrader, KT-485, is seen as a long-term positive, allowing the development of a molecule with greater selectivity and potency.

Strategic Partnerships

An exclusive agreement with Gilead to develop novel degraders against CDK2 could lead to up to $750M in total payments and tiered royalties on sales.

Negative Factors

Development Disappointments

Sanofi has discontinued development of lead IRAK4 degrader KT-474, removing potential catalysts in AD and HS.

Program Delays

Shifting to an earlier stage molecule in IND enabling studies sets back timelines.

Kymera Therapeutics Business Overview & Revenue Model

Company Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Kymera Therapeutics makes money primarily through the development and potential commercialization of its drug candidates, leveraging its proprietary targeted protein degradation platform. Key revenue streams include research and development collaborations, milestone payments, and potential royalties from partnerships with larger pharmaceutical companies. These partnerships, such as those with Sanofi and Vertex Pharmaceuticals, provide funding and resources needed to advance Kymera's drug candidates through clinical trials. Additionally, as drug candidates progress and potentially receive regulatory approval, the company stands to earn revenue from product sales and licensing agreements.

Kymera Therapeutics Financial Statement Overview

Summary

Kymera Therapeutics exhibits financial challenges typical of many biotechnology firms, characterized by heavy R&D investments leading to negative earnings and cash flow. While the balance sheet reflects a strong equity position, indicating potential for future financing, current operations remain under pressure from ongoing losses and negative cash flows. Investors should be cautious and consider the trajectory of product development and potential for revenue growth in the near future.

Income Statement

Kymera Therapeutics shows a declining revenue growth with a drop from the previous periods, and consistent negative net profit margins indicating an ongoing unprofitable state. The gross profit margin is solid as all revenue translates directly to gross profit due to likely no cost of goods sold, but the EBIT and EBITDA margins are significantly negative, reflecting high operational expenses that overshadow revenues.

Balance Sheet

The company maintains a robust equity position with a strong equity ratio, but the debt-to-equity ratio suggests manageable leverage. However, the return on equity remains negative due to persistent losses, which raises concerns about profitability. The balance sheet shows a solid cash position, but the high liabilities relative to equity warrant caution.

Cash Flow

Kymera Therapeutics faces negative free cash flow, which has deteriorated further, indicating pressure on cash generation. The operating cash flow is significantly negative, raising concerns about the company's ability to fund operations without external financing. The free cash flow to net income ratio is unreliable due to negative values, highlighting cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	58.88M	47.07M	78.59M	46.83M	72.83M	34.03M
Gross Profit	58.88M	47.07M	78.59M	43.85M	70.44M	-28.07M
EBITDA	-232.67M	-216.24M	-143.20M	-151.66M	-97.64M	-43.72M
Net Income	-240.88M	-223.86M	-146.96M	-151.83M	-98.00M	-43.95M
Balance Sheet
Total Assets	918.31M	978.03M	575.76M	603.13M	605.90M	487.18M
Cash, Cash Equivalents and Short-Term Investments	463.15M	488.74M	374.88M	559.49M	567.61M	458.73M
Total Debt	86.33M	87.76M	84.67M	17.34M	17.96M	17.99M
Total Liabilities	132.08M	142.42M	180.79M	112.98M	146.27M	203.29M
Stockholders Equity	786.23M	835.62M	394.97M	490.15M	459.64M	283.89M
Cash Flow
Free Cash Flow	-239.96M	-207.34M	-137.31M	-155.92M	-130.54M	79.03M
Operating Cash Flow	-234.06M	-194.50M	-102.83M	-153.09M	-128.95M	88.13M
Investing Cash Flow	-24.86M	-404.08M	139.89M	20.52M	-99.83M	-422.59M
Financing Cash Flow	255.35M	608.85M	4.19M	153.00M	250.28M	289.26M

Kymera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 44.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Neutral. The current price of 44.12 is below the 20-day moving average (MA) of 46.18, above the 50-day MA of 36.96, and above the 200-day MA of 39.45, indicating a neutral trend. The MACD of 2.54 indicates Positive momentum. The RSI at 54.64 is Neutral, neither overbought nor oversold. The STOCH value of 21.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KYMR.

Kymera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	78 Outperform	$1.84B	12.05	24.71%	―	20.62%	14.08%
KYMR	60 Neutral	$2.87B	―	-32.17%	―	-25.85%	-23.89%
BCRX	60 Neutral	$1.96B	―	18.68%	―	41.67%	75.79%
AGIO	60 Neutral	$1.94B	2.95	60.26%	―	25.96%	―
Sector *	60 Neutral	HK$15.14B	5.56	-7.43%	4.30%	11.60%	-21.06%
BEAM	45 Neutral	$1.69B	―	-38.04%	―	-82.38%	-164.76%
IRON	43 Neutral	$1.89B	―	-23.34%	―	―	-14.19%

Kymera Therapeutics Corporate Events

Kymera Therapeutics Announces Public Offering to Raise Funds

On June 26, 2025, Kymera Therapeutics announced an underwritten public offering of its common stock and pre-funded warrants, expected to raise approximately $237.3 million, with the potential to increase to $272.7 million if underwriters exercise their options fully. The proceeds will be used to advance Kymera’s clinical and preclinical degrader programs and for general corporate purposes. The offering is anticipated to close on June 30, 2025, subject to customary conditions, and is part of Kymera’s strategy to fund operations into mid-2028.

The most recent analyst rating on (KYMR) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Holds Annual Shareholder Meeting

On June 25, 2025, Kymera Therapeutics held its Annual Meeting of Shareholders, where three key proposals were voted on. Shareholders elected Jeffrey Albers and Felix J. Baker as Class II directors for a three-year term, approved the compensation of named executive officers on a non-binding basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (KYMR) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Partners with Gilead for Oncology Treatment

On June 25, 2025, Kymera Therapeutics announced an exclusive option and license agreement with Gilead Sciences to develop novel oral molecular glue CDK2 degraders for oncology treatment, including breast cancer. The agreement could bring Kymera up to $750 million in payments and royalties, with Kymera leading research activities. This collaboration aims to advance cancer treatment by selectively targeting and degrading disease-driving proteins, potentially improving care for patients with high unmet medical needs.

The most recent analyst rating on (KYMR) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Advances KT-485 in Sanofi Collaboration

On June 25, 2025, Kymera Therapeutics announced an update on its collaboration with Sanofi, highlighting the advancement of KT-485, an oral IRAK4 degrader, into clinical studies for immuno-inflammatory diseases. This decision, which includes a $20 million milestone achievement for Kymera, marks a strategic shift from KT-474 to KT-485, reflecting its superior preclinical profile and potential to transform immunology treatments. The collaboration could yield up to $975 million in clinical, regulatory, and commercial milestones, positioning Kymera strongly in the biopharmaceutical industry.

The most recent analyst rating on (KYMR) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Discusses Phase 1 Study Results

On June 2, 2025, Kymera Therapeutics held a conference call to discuss the results of their Phase 1 study of KT-621, an oral STAT6 degrader for immuno-inflammatory diseases. The study’s findings are part of Kymera’s strategy to disrupt conventional treatment paradigms in immunology, potentially impacting the company’s market positioning and offering new opportunities for stakeholders.

The most recent analyst rating on (KYMR) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Announces Positive Phase 1 Study Results

On June 2, 2025, Kymera Therapeutics announced positive results from their Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader aimed at treating immuno-inflammatory diseases. The study demonstrated robust STAT6 degradation in blood and skin, with a favorable safety profile comparable to placebo, and showed potential for KT-621 to be a transformative treatment for Th2 diseases. The company plans to advance KT-621 into Phase 1b and Phase 2b trials for atopic dermatitis and asthma, respectively, in late 2025 and early 2026.

The most recent analyst rating on (KYMR) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Introduces KT-579 Targeting IRF5

On May 9, 2025, Kymera Therapeutics announced the introduction of KT-579, an oral degrader targeting IRF5, with potential applications in rheumatic and autoimmune diseases, expected to enter Phase 1 trials in early 2026. The company also reported progress in its KT-621 and KT-474 programs, including a $20 million milestone payment from Sanofi for the IRAK4 collaboration, and a strategic decision to focus resources on the STAT6 and IRF5 programs, extending its financial runway into 2028.